Ocular Hypertension

Researchers in Wheaton, Ill., reported that patients with age-related macular degeneration were more likely to develop glaucoma and its risk factor, ocular hypertension, when treated repeatedly and frequently with anti-VEGF intravitreal injections.

KOLOA, Hawaii — At Hawaiian Eye 2020, Christine L. Larsen, MD, discusses her presentation on the role of medical therapy as primary treatment of glaucoma and ocular hypertension vs. selective laser trabeculoplasty as first-line treatment.

It’s not unusual for us to have more than three dozen patients on our schedules the morning after a typical cataract surgery day. Because the vast majority are doing well 1 day postop, these are usually brief examinations.

No significant difference was seen in efficacy and safety of prostaglandin analogues when comparing original and generics, according to a systematic review published in Ophthalmology Glaucoma.

Regulatory bodies in Hong Kong and Argentina have approved Vyzulta for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.

Vyzulta has been approved in Mexico for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.

A topical ocular formulation of AKB-9778 given as an adjunctive therapy reduced IOP and was well tolerated in patients with ocular hypertension or primary open-angle glaucoma, according to a press release from Aerpio Pharmaceuticals.

Ophthalmology’s armamentarium in the United States grew in 2019 with FDA approvals in retina and glaucoma treatment, as well as an approval for the first trifocal IOL.

The European Medicines Agency has accepted and will review the marketing authorization application for Roclanda, Aerie Pharmaceuticals announced in a press release.

In March, the FDA approved Aerie Pharmaceuticals’ netarsudil and latanoprost compound for the treatment of glaucoma and ocular hypertension. The news was the most-read glaucoma article on Healio/OSN in 2019.